Novo Nordisk announced phase 1b/2a clinical trial results for amycretin this morning. Patients taking the GLP-1 drug lost an average of 9.7% of their weight in 36 weeks. This is the best news Novo ...

Matt and Ross Duffer want to clear up any confusion: Yes, the fifth and final season of “Stranger Things” is coming this year. As a matter of fact, it may be even sooner than expected.

Novo Nordisk has reported 22% weight loss in people who received weekly amycretin injections for 36 weeks, triggering an 11% jump in the Danish drugmaker’s share price in premarket trading.

A father was left in tears over a random act of kindness from a stranger during a family breakfast. Doctor J Mack Slaughter was at a restaurant in Texas with his wife and three children when they ...

Novo Nordisk A/S rose the most since August 2023 after its experimental shot delivered as much as 22% weight loss in an early-stage trial, boosting investors’ hopes for the drugmaker’s pipeline.

At this point it seems pretty obvious that Stranger Things will return in the latter half of 2025, which would make it over three years since season 4 aired. That’s old news at this point ...

Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it gave to pharmacy firms, obesity charities and other professional bodies ...

Patients to pay no more than $35 a month Eli Lilly, Sanofi previously settled overcharging claims Novo Nordisk denies wrongdoing, pledges affordable insulin Jan 27 (Reuters) - Novo Nordisk (NOVOb ...

“I think that the line between actor and celebrity has gotten extremely blurry,” the “Stranger Things” star said. “And I think in some ways a celebrity is someone where their personality ...

Europe's largest pharmaceutical firm, Novo Nordisk, revealed positive trial results for its next-generation obesity drug, amycretin, marking a major step in its competition within the increasingly ...

Results of early-stage trial of injectable amycretin Novo shares jump as much as 13% to a one-month high Novo faces strong competition in obesity drugs from Eli Lilly Jan 24 (Reuters ...